Distinct prognostic values of ALDH1 isoenzymes in breast cancer

Tumor Biology

Volumn 36, Issue 4, 2015, Pages 2421-2426

  Wu, Shaokun ^a,b   Xue, Weiping ^a,b   Huang, Xiaobo ^a,b   Yu, Xiaoli ^a,b   Luo, Ming ^a,b   Huang, Ying ^a,b   Liu, Yimin ^a,b   Bi, Zhuofei ^a,b   Qiu, Xingsheng ^a,b   Bai, Shoumin ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

ALDH1; Breast cancer; Cancer stem cell; KM plotter; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; ISOENZYME; MESSENGER RNA; RETINAL DEHYDROGENASE; TUMOR MARKER;

ALTERNATIVE RNA SPLICING; BIOSYNTHESIS; BREAST TUMOR; CANCER STEM CELL; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; HUMAN; KAPLAN MEIER METHOD; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ALTERNATIVE SPLICING; BREAST NEOPLASMS; DATABASES, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; KAPLAN-MEIER ESTIMATE; NEOPLASTIC STEM CELLS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETINAL DEHYDROGENASE; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84936768293     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2852-6     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
2. Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26.
3. Coleman RE, Gregory W, Marshall H, Wilson C, Holen I. The metastatic microenvironment of breast cancer: clinical implications. Breast. 2013;22 Suppl 2:S50–6.
4. Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta. 2009;1792:380–91.
5. Kakarala M, Wicha MS. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J Clin Oncol. 2008;26:2813–20.
6. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.
7. Clarke MF. Self-renewal and solid-tumor stem cells. Biol Blood Marrow Transplant. 2005;11:14–6.
8. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17:313–9.
9. Douville J, Beaulieu R, Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev. 2009;18:17–25.
10. Ma I, Allan AL. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Rev. 2011;7:292–306.
11. Ehlers CL. Variations in ADH and ALDH in Southwest California Indians. Alcohol Res Health. 2007;30:14–7.
12. Vasiliou V, Thompson DC, Smith C, Fujita M, Chen Y. Aldehyde dehydrogenases: from eye crystallins to metabolic disease and cancer stem cells. Chem Biol Interact. 2013;202:2–10.
13. Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto RA. Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med. 2012;52:735–46.
14. Gaur P, Sceusi EL, Samuel S, et al. Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology. 2011;141:1728–37.
15. Owens BM, Zhu YX, Suen TC, et al. Specific homeodomain-DNA interactions are required for HOX11-mediated transformation. Blood. 2003;101:4966–74.
16. Kim YS, Jung MJ, Ryu DW, Lee CH. Clinicopathologic characteristics of breast cancer stem cells identified on the basis of aldehyde dehydrogenase 1 expression. J Breast Cancer. 2014;17:121–8.
17. Kang EJ, Jung H, Woo OH, et al. Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. Neoplasma. 2014;61:352–62.
18. Zhong Y, Shen S, Zhou Y, et al. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype. Med Oncol. 2014;31:864.
19. Charafe-Jauffret E, Ginestier C, Bertucci F, et al. ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. Cancer Res. 2013;73:7290–300.
20. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res. 2010;16:45–55.
21. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1:555–67.
22. Gyorffy B, Lanczky A, Eklund AC, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725–31.
23. Gyorffy B, Benke Z, Lanczky A, et al. RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat. 2012;132:1025–34.
24. Liu M, Wang G, Gomez-Fernandez CR, Guo S. GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. Plos One. 2012;7:e46410.
25. Tilghman SL, Townley I, Zhong Q, et al. Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness. Mol Cell Proteomics. 2013;12:2440–55.
26. Zhou C, Zhong Q, Rhodes LV, et al. Proteomic analysis of acquired tamoxifen resistance in MCF-7 cells reveals expression signatures associated with enhanced migration. Breast Cancer Res. 2012;14:R45.
27. Maciejczyk A, Szelachowska J, Czapiga B, et al. Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis. J Histochem Cytochem. 2013;61:330–9.
28. Maciejczyk A, Lacko A, Ekiert M, et al. Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. Histol Histopathol. 2013;28:513–24.
29. Maciejczyk A, Jagoda E, Wysocka T, et al. ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome. Pathol Oncol Res. 2012;18:331–42.
30. Adam MA. New prognostic factors in breast cancer. Adv Clin Exp Med. 2013;22:5–15.
31. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact. 2000;129:1–19.
32. Ginestier C, Wicinski J, Cervera N, et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle. 2009;8:3297–302.
33. Burger PE, Gupta R, Xiong X, et al. High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells. 2009;27:2220–8.
34. Chute JP, Muramoto GG, Whitesides J, et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006;103:11707–12.
35. Krupenko NI, Dubard ME, Strickland KC, Moxley KM, Oleinik NV, Krupenko SA. ALDH1L2 is the mitochondrial homolog of 10-formyltetrahydrofolate dehydrogenase. J Biol Chem. 2010;285:23056–63.
36. Xu SL, Zeng DZ, Dong WG, et al. Distinct patterns of ALDH1A1 expression predict metastasis and poor outcome of colorectal carcinoma. Int J Clin Exp Pathol. 2014;7:2976–86.
37. Yang L, Ren Y, Yu X, et al. ALDH1A1 defines invasive cancer stem-like cells and predicts poor prognosis in patients with esophageal squamous cell carcinoma. Mod Pathol. 2014;27:775–83.
38. Wang K, Chen X, Zhan Y, et al. Increased expression of ALDH1A1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol. 2013;30:574.
39. Li XS, Xu Q, Fu XY, Luo WS. ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer. 2014;14:705.
40. Xu J, Muller S, Nannapaneni S, et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer. 2012;48:1682–91.
41. Keymoosi H, Gheytanchi E, Asgari M, Shariftabrizi A, Madjd Z. ALDH1 in combination with CD44 as putative cancer stem cell markers are correlated with poor prognosis in urothelial carcinoma of the urinary bladder. Asian Pac J Cancer Prev. 2014;15:2013–20.
42. Mieog JS, de Kruijf EM, Bastiaannet E, et al. Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer. BMC Cancer. 2012;12:42.
43. Neumeister V, Agarwal S, Bordeaux J, Camp RL, Rimm DL. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am J Pathol. 2010;176:2131–8.
44. Liu Y, Lv DL, Duan JJ, et al. ALDH1A1 expression correlates with clinicopathologic features and poor prognosis of breast cancer patients: a systematic review and meta-analysis. BMC Cancer. 2014;14:444.